Teva Pharmaceutical Industries has been granted a patent for a method of testing and manufacturing dry powder inhalers. The method involves illuminating the discharged dry powder plume with electromagnetic radiation and capturing images to determine the geometric and dynamic characteristics of the plume. This information is then used to modify the design of the inhaler to achieve the desired characteristics. GlobalData’s report on Teva Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Teva Pharmaceutical Industries, Cancer treatment biomarkers was a key innovation area identified from patents. Teva Pharmaceutical Industries's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Method of testing and manufacturing dry powder inhalers

Source: United States Patent and Trademark Office (USPTO). Credit: Teva Pharmaceutical Industries Ltd

A recently granted patent (Publication Number: US11771851B2) describes a method for manufacturing a dry powder inhaler that can discharge a dose of medication in the form of a dry powder plume. The method involves several steps to ensure the inhaler meets the desired plume characteristics.

First, a prototype inhaler is created according to a specific design and filled with a dry powder formulation. This prototype is then tested using a unique method. The inhaler is activated to release a dose of the dry powder, and the resulting plume is illuminated with electromagnetic radiation, such as visible light or a laser. Images of the illuminated plume are captured and processed to determine the plume's geometric and dynamic characteristics.

Based on the processed data, which may differ from the desired characteristics, the design of the inhaler is modified to create a second prototype with the desired plume characteristics. This iterative process allows for the optimization of the inhaler's design to ensure it delivers the medication effectively.

The testing method involves capturing a series of images at regular intervals, typically between 300 to 1,000 Hz. The angular orientation of the plume's outer envelope shape is analyzed, as well as the angle of deviation from the mouthpiece's orientation axis. The cross-sectional area of the plume at a specific distance from the discharge source is also analyzed, along with the powder concentration distribution across a given cross-section of the plume.

The design adjustments aim to minimize the angle of deviation of the plume's central axis, reduce the cross-sectional area of the plume, and alter the powder concentration distribution. For example, the design may be adjusted to increase the powder concentration in the central region of the cross-section.

The patent also mentions a specific type of dry powder inhaler called a breath-actuated inhaler, which includes an airflow adaptor. The design of the adaptor can be modified by adjusting the ratio of cross-sectional areas between the first and second conduits, allowing for the desired plume characteristics.

In addition to modifying the design, the processed plume characteristics are compared to the desired characteristics, and the second inhaler is fabricated according to the modified design.

Overall, this patent presents a method for manufacturing dry powder inhalers that ensures the desired plume characteristics are achieved through iterative testing and design adjustments. This approach can lead to improved inhaler performance and medication delivery.

To know more about GlobalData’s detailed insights on Teva Pharmaceutical Industries, buy the report here.

This content was updated on 25 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies